uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA’s Breakthrough ...
The last time I wrote an article on uniQure (QURE) it was with respect to a Seeking Alpha article entitled "uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts". With respect ...
uniQure announces FDA's Breakthrough Therapy designation for AMT-130, with promising Phase I/II trial safety data and upcoming regulatory updates. uniQure N.V. has announced that its gene therapy ...
uniQure N.V. has announced progress regarding its investigational gene therapy AMT-130 for Huntington's disease, aligning with the FDA on key components necessary for a Biologics License Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results